Jaguar Animal Health (NASDAQ:JAGX) Share Price Passes Below 50 Day Moving Average – Should You Sell?

Jaguar Animal Health, Inc. (NASDAQ:JAGX)’s share price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.93 and traded as low as $0.59. Jaguar Animal Health shares last traded at $0.6320, with a volume of 215,884 shares trading hands.

Analyst Ratings Changes

Several brokerages recently weighed in on JAGX. Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, January 22nd. Wall Street Zen cut shares of Jaguar Animal Health to a “strong sell” rating in a research report on Friday, January 23rd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $60.00.

Jaguar Animal Health Trading Up 7.9%

The firm has a market capitalization of $2.36 million, a price-to-earnings ratio of -0.02 and a beta of 0.09. The business’s fifty day moving average is $0.93 and its 200 day moving average is $1.53. The company has a quick ratio of 0.52, a current ratio of 0.81 and a debt-to-equity ratio of 4.08.

Jaguar Animal Health (NASDAQ:JAGX) last released its earnings results on Friday, November 14th. The biotechnology company reported ($6.28) EPS for the quarter, missing the consensus estimate of ($5.08) by ($1.20). The firm had revenue of $3.08 million during the quarter, compared to the consensus estimate of $3.73 million. Jaguar Animal Health had a negative net margin of 341.90% and a negative return on equity of 1,194.94%. Equities analysts predict that Jaguar Animal Health, Inc. will post -0.8 earnings per share for the current year.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.